UNSPSC 51263106: Carteolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8NF31401XG, chemically known as 2(1h)-quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro- but generally known as carteolol, which bears US NIH Compound Identifier 2583. Carteolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Carteolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06150MIG.

UNSPSC 51263106 Carteolol is a Commodity code nominally for a specific ophthalmic beta-blocker medication, but recent state and local solicitation activity under this code does not reflect pharmaceutical procurement aligned with the code's clinical name. The two recent opportunities posted under this code—a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI exploring direct-to-manufacturer prescription fulfillment models—represent public health and pharmacy benefit management initiatives unrelated to carteolol or its therapeutic use. The mismatch suggests either systematic misclassification of pharmaceutical procurements at the issuing bodies, or that this code is serving as a catch-all placeholder for state and local health agencies purchasing medications and pharmacy-related services outside conventional pharmaceutical distribution channels.

The recent activity spans one Florida county health authority and one state health commission, with the Florida opportunity (IFB 60459723LAS, due July 26, 2023) seeking annual delivery of 1,900 units of naloxone and 800 safe drug deactivation systems on a two-year contract with optional one-year renewal, and the Texas opportunity (RFI HHS0017013, posted April 3, 2026) functioning as exploratory market research into direct contracting between state pharmacy programs and manufacturers without pharmacy benefit manager intermediaries. Neither solicitation involves carteolol or standard ophthalmic pharmaceutical procurement. The code shows minimal recent activity overall, and what does appear operates in niche or pilot program contexts rather than routine pharmaceutical supply. Firms evaluating this code should verify UNSPSC alignment with issuing bodies before pursuing—the current classification pattern suggests opportunities may land here by administrative error rather than procurement intent.